MHUA
MHUA
Meihua International Medical Technologies Co., Ltd.Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $37.98M ▼ | $9.37M ▼ | $3.15M ▼ | 8.28% ▼ | $9.86 ▼ | $3.51M ▼ |
| Q4-2024 | $51.57M ▲ | $9.61M ▲ | $6.13M ▲ | 11.88% ▲ | $21 ▲ | $9.4M ▲ |
| Q2-2024 | $45.34M ▼ | $9.24M ▼ | $4.72M ▲ | 10.4% ▲ | $17 ▼ | $6.18M ▲ |
| Q4-2023 | $48.91M ▲ | $10.41M ▲ | $4.56M ▼ | 9.33% ▼ | $19.06 ▼ | $5.75M ▼ |
| Q2-2023 | $48.19M | $8M | $7.06M | 14.65% | $30 | $9.53M |
What's going well?
The company is still profitable despite the sharp drop in sales. Other income provided a helpful boost, and there are no major one-time charges distorting results.
What's concerning?
Revenue fell sharply, profits were cut in half, and margins are getting squeezed. Costs are not falling as fast as sales, and share dilution is hurting per-share results.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $15.55M ▼ | $190.58M ▲ | $25.64M ▼ | $164.95M ▲ |
| Q4-2024 | $15.96M ▼ | $186.24M ▲ | $27.26M ▼ | $158.98M ▲ |
| Q2-2024 | $18.49M ▲ | $179.16M ▲ | $29.59M ▲ | $149.57M ▲ |
| Q4-2023 | $16.93M ▼ | $171.92M ▲ | $25.08M ▲ | $146.33M ▲ |
| Q2-2023 | $17.86M | $162.61M | $23.22M | $138.89M |
What's financially strong about this company?
MHUA has a huge cushion of equity, very little debt, and most assets are cash or receivables. Liquidity is excellent, and the company has a long track record of profits.
What are the financial risks or weaknesses?
Debt rose slightly this quarter, and cash dipped a bit, but these are minor. Receivables are a large portion of assets, so slow-paying customers could be a risk if the economy turns.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $3.15M ▼ | $-19.8M ▼ | $12.18M ▲ | $6.62M ▲ | $-386.49K ▼ | $-9.91M ▼ |
| Q4-2024 | $6.13M ▲ | $13.62M ▲ | $-15M ▼ | $79.43K ▼ | $0 ▼ | $13.5M ▲ |
| Q2-2024 | $4.72M ▲ | $1.02M ▼ | $-5.42M ▲ | $6.13M ▲ | $781.88K ▲ | $1.01M ▼ |
| Q4-2023 | $4.56M ▼ | $7.7M ▲ | $-8.59M ▼ | $-15.55K ▼ | $-467.17K ▲ | $7.52M ▲ |
| Q2-2023 | $7.06M | $-5.42M | $-3.87M | $721.68K | $-8.88M | $-10.01M |
What's strong about this company's cash flow?
The company still has $16.9 million in cash, and capital spending is low, so it can adjust quickly if needed.
What are the cash flow concerns?
Cash flow swung from positive to negative, working capital is draining cash, and the company now needs to borrow just to keep operating. If this continues, cash could run out soon.
5-Year Trend Analysis
A comprehensive look at Meihua International Medical Technologies Co., Ltd.'s financial evolution and strategic trajectory over the past five years.
The company combines a broad, established product portfolio and long operating history with a notably strong balance sheet: low debt, ample liquidity, and growing equity. It remains consistently profitable despite recent margin pressure and has recently delivered a marked improvement in operating and free cash flow. Certifications, regulatory approvals, and deep customer relationships, plus active R&D and digital initiatives like the Speed Fox platform and the Hainan import hub, provide a platform for potential future growth.
Key concerns center on declining profitability, shrinking margins, and falling earnings per share against a backdrop of largely flat revenue. The business has a history of volatile and sometimes weak cash generation, operates in a highly competitive and price-sensitive segment, and faces ongoing regulatory and market-access risks. Volatility in intangibles and the need to address stock-market listing issues, including a reverse split and prior delisting notices, add governance and capital-market uncertainty.
The overall picture is of a company with solid financial foundations but under operational and competitive pressure. Its strong balance sheet and recent cash flow recovery give it time and flexibility to adjust strategy, while current innovation and expansion initiatives offer potential upside if they translate into higher-margin growth. At the same time, the outlook is tempered by the need to stabilize margins, demonstrate consistent cash generation, and successfully execute new projects in a challenging, commoditized market environment.
About Meihua International Medical Technologies Co., Ltd.
https://www.meihuamed.comMeihua International Medical Technologies Co., Ltd. engages in the manufacture and marketing of medical consumables in the People's Republic of China. It offers class I, II, and III disposable medical devices. The company's products include non-bottled products, such as brushes and ID bracelets; and polyethylene bottled products, such as eye drop and tablet bottles.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $37.98M ▼ | $9.37M ▼ | $3.15M ▼ | 8.28% ▼ | $9.86 ▼ | $3.51M ▼ |
| Q4-2024 | $51.57M ▲ | $9.61M ▲ | $6.13M ▲ | 11.88% ▲ | $21 ▲ | $9.4M ▲ |
| Q2-2024 | $45.34M ▼ | $9.24M ▼ | $4.72M ▲ | 10.4% ▲ | $17 ▼ | $6.18M ▲ |
| Q4-2023 | $48.91M ▲ | $10.41M ▲ | $4.56M ▼ | 9.33% ▼ | $19.06 ▼ | $5.75M ▼ |
| Q2-2023 | $48.19M | $8M | $7.06M | 14.65% | $30 | $9.53M |
What's going well?
The company is still profitable despite the sharp drop in sales. Other income provided a helpful boost, and there are no major one-time charges distorting results.
What's concerning?
Revenue fell sharply, profits were cut in half, and margins are getting squeezed. Costs are not falling as fast as sales, and share dilution is hurting per-share results.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $15.55M ▼ | $190.58M ▲ | $25.64M ▼ | $164.95M ▲ |
| Q4-2024 | $15.96M ▼ | $186.24M ▲ | $27.26M ▼ | $158.98M ▲ |
| Q2-2024 | $18.49M ▲ | $179.16M ▲ | $29.59M ▲ | $149.57M ▲ |
| Q4-2023 | $16.93M ▼ | $171.92M ▲ | $25.08M ▲ | $146.33M ▲ |
| Q2-2023 | $17.86M | $162.61M | $23.22M | $138.89M |
What's financially strong about this company?
MHUA has a huge cushion of equity, very little debt, and most assets are cash or receivables. Liquidity is excellent, and the company has a long track record of profits.
What are the financial risks or weaknesses?
Debt rose slightly this quarter, and cash dipped a bit, but these are minor. Receivables are a large portion of assets, so slow-paying customers could be a risk if the economy turns.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $3.15M ▼ | $-19.8M ▼ | $12.18M ▲ | $6.62M ▲ | $-386.49K ▼ | $-9.91M ▼ |
| Q4-2024 | $6.13M ▲ | $13.62M ▲ | $-15M ▼ | $79.43K ▼ | $0 ▼ | $13.5M ▲ |
| Q2-2024 | $4.72M ▲ | $1.02M ▼ | $-5.42M ▲ | $6.13M ▲ | $781.88K ▲ | $1.01M ▼ |
| Q4-2023 | $4.56M ▼ | $7.7M ▲ | $-8.59M ▼ | $-15.55K ▼ | $-467.17K ▲ | $7.52M ▲ |
| Q2-2023 | $7.06M | $-5.42M | $-3.87M | $721.68K | $-8.88M | $-10.01M |
What's strong about this company's cash flow?
The company still has $16.9 million in cash, and capital spending is low, so it can adjust quickly if needed.
What are the cash flow concerns?
Cash flow swung from positive to negative, working capital is draining cash, and the company now needs to borrow just to keep operating. If this continues, cash could run out soon.
5-Year Trend Analysis
A comprehensive look at Meihua International Medical Technologies Co., Ltd.'s financial evolution and strategic trajectory over the past five years.
The company combines a broad, established product portfolio and long operating history with a notably strong balance sheet: low debt, ample liquidity, and growing equity. It remains consistently profitable despite recent margin pressure and has recently delivered a marked improvement in operating and free cash flow. Certifications, regulatory approvals, and deep customer relationships, plus active R&D and digital initiatives like the Speed Fox platform and the Hainan import hub, provide a platform for potential future growth.
Key concerns center on declining profitability, shrinking margins, and falling earnings per share against a backdrop of largely flat revenue. The business has a history of volatile and sometimes weak cash generation, operates in a highly competitive and price-sensitive segment, and faces ongoing regulatory and market-access risks. Volatility in intangibles and the need to address stock-market listing issues, including a reverse split and prior delisting notices, add governance and capital-market uncertainty.
The overall picture is of a company with solid financial foundations but under operational and competitive pressure. Its strong balance sheet and recent cash flow recovery give it time and flexibility to adjust strategy, while current innovation and expansion initiatives offer potential upside if they translate into higher-margin growth. At the same time, the outlook is tempered by the need to stabilize margins, demonstrate consistent cash generation, and successfully execute new projects in a challenging, commoditized market environment.

CEO
Lee Leyi
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-11-24 | Reverse | 1:100 |
Price Target
Institutional Ownership
XTX TOPCO LTD
Shares:32.03K
Value:$309.43K
RENAISSANCE TECHNOLOGIES LLC
Shares:30.6K
Value:$295.6K
MAREX GROUP PLC
Shares:25.2K
Value:$243.42K
Summary
Showing Top 3 of 8

